Avenzo Therapeutics

Executive Summary

Avenzo Therapeutics is a clinical-stage oncology company leveraging structure-based drug design to develop next-generation small molecule kinase inhibitors aimed at overcoming resistance in solid tumors and hematologic malignancies. Founded in 2022 and headquartered in San Diego, the company has raised over $660 million to advance its pipeline. Its lead programs target critical cancer pathways with high selectivity to minimize off-target effects. The company's approach reflects a deep understanding of resistance mechanisms, positioning it as a potential leader in precision oncology. Currently, Avenzo is advancing its lead asset through Phase 1 clinical trials, with initial data expected to demonstrate proof-of-mechanism and early signs of efficacy. The company is also progressing preclinical programs toward IND filings. With a strong financial position and a focused strategy, Avenzo is poised to deliver value through clinical milestones and potential partnerships. Upcoming catalysts include Phase 1 data readouts and the initiation of new clinical programs, which could de-risk the pipeline and attract collaboration interest.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead asset50% success
• Q4 2026IND filing for second program40% success